Charles L. Sawyers, MD, FAACR, explained that the progression from castration-sensitive to castration-resistant prostate cancer occurs, in part, through a lineage switch that converts prostate cancer cells from an adenocarcinoma cell state to a neuroendocrine state.

Byoung Chul Cho, MD, presented updated results from a phase I/II clinical trial of the next-generation KRAS-G12C inhibitor elisrasib, which was designed for faster and stronger target engagement, to afford sustained inhibition, Cho explained.

Elizabeth K. Lee, MD, presented results from a phase I dose-escalation clinical trial testing a combination of the PARP inhibitor olaparib and the ADC DS-8201a, also known as trastuzumab deruxtecan.

During the first Plenary Session on Saturday, Jeanne Tie, MD, spoke about the impact of minimal residual disease (MRD) in guiding clinical trial design for colorectal cancer.

AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), and other speakers highlighted the impressive work of the AACR and its members, as thousands of enthusiastic researchers from around the world gathered to hear the state of the cancer research union.